Target Name: DCLK3
NCBI ID: G85443
Other Name(s): DCLK3 variant 2 | DCLK3_HUMAN | Doublecortin-like kinase 3 | Doublecortin like kinase 3, transcript variant 2 | Serine/threonine-protein kinase DCLK3 | DCK3 | Doublecortin domain-containing protein 3C | doublecortin-like and CAM kinase-like 3 | Doublecortin and CaM kinase-like 3 | CLR | doublecortin domain-containing protein 3C | Serine/threonine-protein kinase DCLK3 (isoform 2) | doublecortin and CaM kinase-like 3 | DCDC3C | KIAA1765 | DCAMKL3 | Doublecortin-like and CAM kinase-like 3 | doublecortin like kinase 3 | CLICK-I,II-related

DCLK3: A Potential Drug Target and Biomarker

Introduction

DCLK3 (doublecortin-like kinase 3) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of cell proliferation and has been involved in the development of various diseases, including cancer. The identification of DCLK3 as a potential drug target has led to a significant increase in the number of research articles and studies aimed at understanding its functions and potential therapeutic applications. In this article, we will provide an overview of DCLK3, its functions, and its potential as a drug target and biomarker.

Functions of DCLK3

DCLK3 is a non-coding RNA molecule that is expressed in various tissues and cells. It is a key regulator of cell proliferation and has been involved in the development of various diseases, including cancer. DCLK3 has been shown to play a role in the regulation of cell cycle progression, apoptosis, and angiogenesis.

One of the key functions of DCLK3 is its role in cell proliferation. DCLK3 has been shown to promote the growth and survival of cancer cells by inhibiting the apoptosis that occurs when cells reach their maximum size and have not been damaged enough to continue to grow. This is achieved by increasing the expression of DCLK3, which leads to the inhibition of the apoptosis-associated protein Bcl-2, thereby promoting the survival of cancer cells.

DCLK3 is also involved in the regulation of apoptosis, which is the process by which cells die. DCLK3 has been shown to induce apoptosis in various cell types, including cancer cells, and has been shown to play a role in the development of neurodegenerative diseases.

DCLK3 is also involved in the regulation of angiogenesis, which is the process by which new blood vessels form in the body. DCLK3 has been shown to promote the formation of new blood vessels in various organs and has been implicated in the development of various diseases, including cancer.

Potential Drug Target

DCLK3 has been identified as a potential drug target due to its involvement in the regulation of cell proliferation and apoptosis. Drugs that target DCLK3 have been shown to have therapeutic applications in various diseases, including cancer.

One of the most well-known drugs that targets DCLK3 is the inhibitor of DCLK3, known as MK-8628. MK-8628 is a small molecule that inhibits the activity of DCLK3 and has been shown to have therapeutic applications in various diseases, including cancer.

In addition to MK-8628, other drugs that target DCLK3 include inhibitors of DCLK3's downstream targets, such as the protein kinase Afr-3, which has been shown to have therapeutic applications in neurodegenerative diseases.

Biomarker

DCLK3 has also been identified as a potential biomarker for various diseases, including cancer. The levels of DCLK3 have been shown to be elevated in various types of cancer, including breast, lung, and ovarian cancer. This suggests that DCLK3 may be a useful biomarker for the diagnosis and treatment of cancer.

In addition to its potential as a drug target, DCLK3 has also been shown to be a potential biomarker for various diseases, including cancer. The levels of DCLK3 have been shown to be elevated in various types of cancer, including breast, lung, and ovarian cancer. This suggests that DCLK3 may be a useful biomarker for the diagnosis and treatment of cancer.

Conclusion

DCLK3 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is involved in the regulation of cell proliferation and apoptosis and has

Protein Name: Doublecortin Like Kinase 3

More Common Targets

DCLRE1A | DCLRE1B | DCLRE1C | DCN | DCP1A | DCP1B | DCP2 | DCPS | DCST1 | DCST1-AS1 | DCST2 | DCSTAMP | DCT | DCTD | DCTN1 | DCTN1-AS1 | DCTN2 | DCTN3 | DCTN4 | DCTN5 | DCTN6 | DCTPP1 | DCUN1D1 | DCUN1D2 | DCUN1D3 | DCUN1D4 | DCUN1D5 | DCX | DCX (DDB1-CUL4-X-box) E3 protein ligase complex | DCX DET1-COP1 ubiquitin ligase complex | DCX(DCAF15) E3 protein ligase complex | DCXR | DDA1 | DDAH1 | DDAH2 | DDB1 | DDB2 | DDC | DDC-AS1 | DDD core complex | DDHD1 | DDHD2 | DDI1 | DDI2 | DDIAS | DDIT3 | DDIT4 | DDIT4L | DDN | DDO | DDOST | DDR1 | DDR2 | DDRGK1 | DDT | DDTL | DDX1 | DDX10 | DDX11 | DDX11-AS1 | DDX11L1 | DDX11L10 | DDX11L2 | DDX11L8 | DDX11L9 | DDX12P | DDX17 | DDX18 | DDX18P1 | DDX19A | DDX19A-DT | DDX19B | DDX20 | DDX21 | DDX23 | DDX24 | DDX25 | DDX27 | DDX28 | DDX31 | DDX39A | DDX39B | DDX39B-AS1 | DDX3P1 | DDX3X | DDX3Y | DDX4 | DDX41 | DDX42 | DDX43 | DDX46 | DDX47 | DDX49 | DDX5 | DDX50 | DDX50P1 | DDX51 | DDX52 | DDX53 | DDX54